Navigation Links
Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion

BALTIMORE, Feb. 23, 2012 /PRNewswire/ --

Event details:
February 25, 2012
12 p.m. – 1:15 p.m.
Renaissance Palm Springs Hotel
Catalina/Madera Room
Palm Springs, CA

Ameritox(SM), the nation's leader in pain medication monitoring, will sponsor a safe opioid prescribing symposium highlighting emerging trends and technologies in medication monitoring at the American Academy of Pain Medicine's (AAPM) 28th Annual Meeting in Palm Springs, California.

"For clinicians treating the tens of millions of people suffering from chronic pain, helping patients find safe, effective relief is the ultimate priority," said Dr. Harry Leider, Chief Medical Officer at Ameritox.

The symposium will focus on a new set of expert consensus recommendations, to be presented during a poster session at the meeting, which answer critical questions in pain monitoring. These recommendations are intended to add specifics to previous clinical guidelines, with the goal of providing physicians guidance on how to use urine drug monitoring to improve patient outcomes.

The symposium will also provide attendees with the latest data on the emerging use of urine opioid levels in helping physicians assess patients for adherence to a chronic opioid regimen. This segment will highlight Ameritox research, which resulted in a proprietary monitoring tool, Rx Guardian CD(SM), being made available to clinicians who prescribe opioids to patients with chronic pain to help reduce the risk of opioid misuse, abuse and diversion. Rx Guardian CD(SM) consists of a reference database of more than 1,000 pain patients who were clinically assessed as adherent to their prescription regimens. It then displays the results to allow physicians to see, at a glance, how a specific patient's drug monitoring results compare to patients in the database.

"Physicians are on the front lines of both patient care and drug abuse prevention," Leider said. "Providing tools, supported by quality research, to help physicians evaluate whether their patients take the proper medications as directed should improve patient care and help keep prescription painkillers out of the hands of those who abuse these medications." 

Topics and Faculty include:

New Expert Consensus Recommendations on the Use of Pain Medication Monitoring (Urine Drug Testing)
Steven Passik, PhD and John Peppin, DO, FACP

Use of Urine Opioid Levels to Assist Physician Assessment of Adherence
Harry Leider, MD, FACPE

About Ameritox

Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx Guardian(SM) – with Rx Guardian CD(SM), the only pain medication screening with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at, on Twitter @Ameritox, or on Facebook at


For more information, contact: Lon Wagner
Office: 336-387-7742
Cell: 757-617-1846



SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients
2. Ameritox® Continues to Advance Industry Leadership
3. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
4. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
5. Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
6. Masimo Reports Fourth Quarter and Full Year 2011 Financial Results; Provides 2012 Financial Guidance
7. Watson Provides Update on Generic Lidoderm® Application
8. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
9. Hill-Rom Reports Fiscal First Quarter Results; Provides Second Quarter and Full Year Financial Outlook
10. MDHI Provides Update on FirstFitness Merger - Operation Expected to Produce 2012 Revenues in Excess of $12 Mil - Warrants of 15.5 Mil Cancelled
11. Validation & Compliance Institute Provides Affordable Online FDA Training
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):